Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent

Rhea-AI Summary

Devonian Health Group (OTCQB: DVHGF) announced on December 4, 2025 the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." Researchers compared Thykamine™ with six widely prescribed anti-inflammatory drugs in an in vitro immune-activated cell model and reported that Thykamine™ inhibited MCP-1, MIP-1α and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested. Effects occurred at lower concentrations and with no detectable cytotoxicity, suggesting a favorable tolerability profile and potential for further therapeutic development targeting chronic inflammatory and fibrotic conditions.

Positive

• In vitro inhibition of MCP-1, MIP-1α, MIP-1β stronger than six comparators
• RANTES suppression comparable or superior to most agents tested
• Active effects observed at lower concentrations without detectable cytotoxicity

Negative

• Evidence limited to an in vitro model without clinical efficacy data
• No human trial results presented to validate translational or safety claims

Key Figures

Compared drugs: 6 anti-inflammatory drugs Chemokine markers: 4 chemokines (MCP-1, MIP-1α, MIP-1β, RANTES) Multi-target efficacy: Greater potency vs all comparators +5 more

8 metrics

Compared drugs 6 anti-inflammatory drugs In vitro comparison against Thykamine™

Chemokine markers 4 chemokines (MCP-1, MIP-1α, MIP-1β, RANTES) Inflammatory markers measured in vitro

Multi-target efficacy Greater potency vs all comparators Inhibition of MCP-1, MIP-1α, MIP-1β

RANTES effect Comparable or superior suppression RANTES secretion vs most agents tested

Cytotoxicity No detectable cytotoxicity Observed at effective concentrations in vitro

Price move -60.5% 24h change before this news

52-week high 0.2138 Pre-news 52-week high level

52-week low 0.01 Pre-news 52-week low level

Market Reality Check

Price: $0.0711 Vol: Volume 10000 is 5.1x the ...

high vol

$0.0711 Last Close

Volume Volume 10000 is 5.1x the 20-day average of 1963, indicating elevated pre-news activity. high

Technical Price at 0.0711 is below the 200-day MA of 0.18 and 66.74% under the 52-week high.

Peers on Argus

Peers showed mixed moves: HRGN -14.03%, PVCT -0.77%, BVAXF +7.73%, while others ...

Peers showed mixed moves: HRGN -14.03%, PVCT -0.77%, BVAXF +7.73%, while others were flat. This dispersion suggests DVHGF’s -60.5% move was stock-specific rather than a sector-wide biotechnology shift.

Market Pulse Summary

This announcement highlights peer-reviewed in vitro data showing Thykamine™ inhibiting key chemokine...

Analysis

This announcement highlights peer-reviewed in vitro data showing Thykamine™ inhibiting key chemokines with greater potency than several standard anti-inflammatory drugs and no detectable cytotoxicity. With the stock at 0.0711, below the 200-day MA of 0.18 and far under the 0.2138 52-week high, the company remains in an early, validation-focused phase. Investors may watch for clinical trial data and regulatory milestones to confirm whether these mechanistic findings translate into patient benefit.

Key Terms

in vitro, corticosteroids, non-steroidal, chemokines, +3 more

7 terms

in vitro medical

"Using an in vitro model of immune-activated cells, they measured secretion"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

corticosteroids medical

"including corticosteroids such as betamethasone, clobetasol, hydrocortisone, prednisone"

Corticosteroids are a class of hormones and synthetic medicines that dial down inflammation and the immune system, acting like a thermostat that lowers the body’s defensive response. They are used to treat conditions from asthma and allergies to autoimmune diseases and severe inflammation; their approved uses, safety profile, and manufacturing costs matter to investors because they affect drug sales, regulatory risk, patent value, and potential liability or demand shifts for healthcare companies.

non-steroidal medical

"and non-steroidal therapies such as crisaborole and pimecrolimus"

Non-steroidal describes a drug or treatment that does not contain steroid hormones or mimic their chemical structure; it’s often used to distinguish medicines that reduce pain, inflammation, or allergic reactions by mechanisms other than steroid action. For investors, this matters because non-steroidal products typically follow different safety profiles, regulatory paths, competition and market niches than steroid-based therapies, affecting development costs, approval risks and commercial potential — like choosing a different recipe that changes cost, taste and shelf life.

chemokines medical

"they measured secretion levels of major chemokines (inflammatory markers) — MCP-1"

Small signaling proteins that act like traffic signals, guiding immune and inflammatory cells to specific locations in the body such as sites of infection, injury or disease. They matter to investors because chemokines are common drug targets and biomarkers: changes in their activity can drive therapeutic strategies, affect clinical trial design and outcomes, and influence regulatory decisions and commercial potential for treatments in immunology, oncology and other fields.

cytotoxicity medical

"at lower concentrations and without detectable cytotoxicity, suggesting a notably"

Cytotoxicity is the ability of a substance to kill or damage living cells. Investors watch cytotoxicity results because they indicate whether a drug or chemical is likely to be effective against targeted cells (for example, cancer cells) and whether it poses safety risks to healthy tissue, which affects clinical success, regulatory approval, and commercial potential—similar to knowing if a powerful weed killer also harms the lawn around the weeds.

autoimmune medical

"manage chronic inflammatory and autoimmune conditions.'' said Dr. André P. Boulet"

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

fibrosis medical

"persistent inflammation can also drive the development of fibrosis—progressive tissue"

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

AI-generated analysis. Not financial advice.

QUÉBEC, Dec. 4, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." The study presents notable evidence supporting the potent multi-target anti-inflammatory properties of Thykamine™, the Corporation's lead pharmaceutical candidate.

The article, published in peer-reviewed BioMedicines Journal and titled, ''Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs'', is now available online at: https://www.mdpi.com/2227-9059/13/12/2938. It was co-authored by Dr. Charles Lynde, Associate Professor in the Department of Medicine at the University of Toronto; Professor (Pr) Louis Flamand, Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval; Vincent McCarty and Dr. John Sampalis, Department of Surgery, McGill University, Montreal, Canada.

In this study, researchers compared the effect of Thykamine™ with six widely prescribed anti-inflammatory drugs (including corticosteroids such as betamethasone, clobetasol, hydrocortisone, prednisone; and non-steroidal therapies such as crisaborole and pimecrolimus). Using an in vitro model of immune-activated cells, they measured secretion levels of major chemokines (inflammatory markers) — MCP-1, MIP-1α, MIP-1β and RANTES — after inflammatory stimulation. Thykamine™ inhibited secretion of MCP-1, MIP-1α, and MIP-1β with significantly greater potency than all comparators and suppressed RANTES secretion to a degree comparable or superior to most agents tested.

Importantly, these effects were observed at lower concentrations and without detectable cytotoxicity, suggesting a notably favorable safety profile. This unique combination of multi-target efficacy and cellular tolerability positions Thykamine™ as a strong candidate for next-generation therapeutic development targeting chronic inflammatory conditions.

A New Paradigm for Inflammation Management

Chronic inflammation contributes to a wide spectrum of medical conditions, ranging from dermatological diseases such as atopic dermatitis (eczema) to gastrointestinal disorders and systemic autoimmune pathologies. When left unresolved, persistent inflammation can also drive the development of fibrosis—progressive tissue scarring that disrupts normal organ architecture and function. Over time, this fibrotic remodeling can lead to irreversible organ damage and failure, representing one of the most serious long-term consequences of chronic inflammatory diseases.

The findings published in Biomedicines reinforce Thykamine™'s potential to address this unmet medical need by offering a plant-derived, multi-mechanistic alternative capable of modulating inflammation across several biologically relevant pathways —potentially impacting both inflammatory and fibrotic processes.

''The results with Thykamine™ are very encouraging. For too long, patients have had to choose between effectiveness and tolerability. Thykamine™ offers a real possibility of bridging that gap — combining potent suppression of harmful inflammation with a gentler safety profile. We believe this could represent a paradigm shift in how we manage chronic inflammatory and autoimmune conditions.'' said Dr. André P. Boulet, PhD, Chairman & CEO of Devonian.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring drug development pathway for prescription botanical drug products.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under a license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec (Quebec) Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Corporations' projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine^TM might not be granted, and, generally, the above "About Devonian" paragraphs, which essentially describes the Corporation's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation refuses any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/devonian-health-group-announces-publication-of-landmark-study-highlighting-thykamine-as-a-promising-new-anti-inflammatory-agent-302632712.html

SOURCE Devonian Health Group Inc.

FAQ

What did Devonian announce on December 4, 2025 about Thykamine (DVHGF)?

Devonian announced a peer-reviewed Biomedicines publication reporting that Thykamine showed multi-target anti-inflammatory activity versus six comparator drugs in an in vitro model.

How did Thykamine perform versus other anti-inflammatory drugs in the study?

Thykamine inhibited MCP-1, MIP-1α, and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested.

Did the Biomedicines study report safety findings for Thykamine (DVHGF)?

The study reported no detectable cytotoxicity at active concentrations in the in vitro assays, suggesting a favorable cellular tolerability profile.

Does the Biomedicines publication provide clinical evidence for Thykamine (DVHGF)?

No; the results are from an in vitro immune-activated cell model and do not include human clinical trial data.

Where can investors read the published Thykamine study for DVHGF?

The article is available online in Biomedicines at the journal website and was published on December 4, 2025.